University of California, San Diego Medical Center, San Diego, CA, USA.
Veterans Affairs Medical Center, VA San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, CA, 92161, USA.
Drugs. 2016 Feb;76(2):187-201. doi: 10.1007/s40265-015-0498-3.
Heart failure is a complex syndrome that has been a major contributor to readmissions into hospitals in the USA. Currently, a large number of medications are being used to treat the symptoms of the disease-digoxin, diuretics, renin-angiotensin-aldosterone system inhibitors, β-blockers, and vasodilators. There is no doubt that the given pharmaceutical therapy has been effective in lowering hospital readmission rates and prolonging life in individual chronic heart failure patients. Despite this, admission rates following heart failure hospitalization remain high, resulting in a substantial financial strain on healthcare institutions. Clearly, there is much room for improvement in heart failure therapy and management in reducing readmission rates. In this review, we address the unmet needs in the current drug treatment of chronic heart failure and describe novel drug targets that are currently under investigation.
心力衰竭是一种复杂的综合征，是导致美国医院患者再次入院的主要原因之一。目前，有大量的药物被用于治疗该疾病的症状——地高辛、利尿剂、肾素-血管紧张素-醛固酮系统抑制剂、β受体阻滞剂和血管扩张剂。毫无疑问，这些药物疗法在降低心力衰竭患者的住院再入院率和延长患者寿命方面是有效的。尽管如此，心力衰竭住院后的入院率仍然很高，这给医疗机构带来了巨大的经济压力。显然，在降低再入院率方面，心力衰竭的治疗和管理还有很大的改进空间。在这篇综述中，我们探讨了当前慢性心力衰竭药物治疗中未满足的需求，并描述了目前正在研究的新的药物靶点。
